TP53 and prostate cancer: Moreover, capivasertib monotherapy in PTEN-deficient intact or castrated prostate cancer mouse models has shown strong anti-tumor effects, and improves survival in an aggressive prostate cancer model driven by PTEN/p53 loss [207].